{"id":"NCT00236899","sponsor":"Eli Lilly and Company","briefTitle":"Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC","officialTitle":"A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2005-10-12","resultsPosted":"2011-09-27","lastUpdate":"2011-09-27"},"enrollment":241,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Breast Cancer (MBC)"],"interventions":[{"type":"DRUG","name":"Gemcitabine","otherNames":["LY188011","Gemzar"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"A: Docetaxel and Gemcitabine (Tri-weekly)","type":"EXPERIMENTAL"},{"label":"B: Paclitaxel and Gemcitabine (Tri-weekly)","type":"EXPERIMENTAL"},{"label":"C: Docetaxel and Gemcitabine (Weekly)","type":"EXPERIMENTAL"},{"label":"D: Paclitaxel and Gemcitabine (Weekly)","type":"EXPERIMENTAL"}],"summary":"Multi-center, randomized Phase III study. 4 arms. 360 Patient to enroll. Purpose is evaluate time to progression disease (PD).","primaryOutcome":{"measure":"Time to Progressive Disease (TTPD) by Treatment Schedule","timeFrame":"Baseline up to 49.84 months","effectByArm":[{"arm":"Treatment Schedule (Weekly)","deltaMin":8.33,"sd":null},{"arm":"Treatment Schedule (3 Weekly)","deltaMin":7.51,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.345"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":34,"countries":["Italy"]},"refs":{"pmids":["23537313"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":59},"commonTop":["Neutropenia","Nausea","Pyrexia","Alopecia","Asthenia"]}}